Jubilant Life Sciences to expand capacity and R&D
Jubilant Life Sciences is expanding its production capacity at Roorkee in Uttaranchal. The company has earmarked Rs 5500 million for capital expenditure (capex) in the […]
Jubilant
Jubilant Life Sciences receives USFDA approval for Amantadine Hydrochloride
Jubilant Life Sciences has received final USFDA approval for Amantadine Hydrochloride tablets, an anti-viral and anti-Parkinsons drug. The drug is a generic version of Symmetrel […]
Jubilant Life Sciences has received USFDA approval for Indocin
Jubilant Life Sciences has received final USFDA approval for the generic version of its non-steroidal anti-inflammatory drug, Indocin. The approval for Indomethacin capsules is a […]
Jubilant Life Sciences receives USFDA approval for Bupropion Hydrochloride
Jubilant Life Sciences through its subsidiary has received final USFDA approval for Bupropion Hydrochloride extended-release tablets, used for the treatment of major depressive disorder and […]
Jubilant Life Sciences receives USFDA approval for Darifenacin
Jubilant Life Sciences has received the final USFDA approval for Darifenacin Extended-Release Tablets, used for the treatment of urinary incontinence. The company has received Abbreviated […]
Jubilant Life Sciences receives USFDA approval for Telmisartan
Jubilant Life Sciences has received USFDA approval for Telmisartan Tablets, used for the treatment of hypertension, in the U.S. market. The final approval is for […]
Jubilant Life Sciences recieves approval for anti-depressant Paxil
Jubilant Life Sciences Ltd has received final approval from USFDA for its generic version of anti-depressant Paxil tablets. The final approval for the abbreviated new […]
Jubliant Life Sciences receives ANDA final approval for Levofloxacin
Jubliant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval for Levofloxacin tablets, 250mg and 500mg, the generic version of Levaquin Tablets. It […]